logo
  

Arrow Electronics Q3 Earnings Rise, Beats Estimates

Arrow Electronics, Inc. (ARW) Wednesday posted higher profit for the third quarter, as net sales grew 11 percent year-over-year.

The group's net income improved to $146.9 million or $1.47 per share from $96.8 million or $0.95 per share a year ago.

Excluding certain items, the company earned $140.2 million or $1.40 per share.

On average, 10 analysts polled by Thomson-Reuters estimated the company's earnings to be $1.31 per share for the quarter. Analysts' estimates typically exclude one-time items.

Quarterly sales increased to $5.61 billion from $5.05 billion last year, while Wall Street expected revenues of $5.40 billion.

Looking forward, for the fourth quarter, the firm expects earnings per share excluding any charges to be in a range of $1.75 - $1.87 , on total sales of $6.1 billion - $6.5 billion. Analysts are looking for earnings of $1.74 per share, on sales of $6.16 billion.

For the full year, the company said at the midpoints of its fourth-quarter guidance ranges, sales and earnings per share, excluding any charges would grow 6 percent and 17 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT